References
- Achtert, G., Scherrmann, J.M., and Christen, M.O., 1989. Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. European journal of drug metabolism and pharmacokinetics, 14 (4), 317–322.
- Arnold, S. and Buckner, F., 2020. Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. Clinical and translational science, 13 (4), 642–645.
- Audemard-Verger, A., et al., 2017. Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis & rheumatology, 69 (9), 1862–1870.
- Ben-Chetrit, E. and Levy, M., 1998. Colchicine: 1998 update. Seminars in arthritis and rheumatism, 28 (1), 48–59.
- Berkun, Y., et al., 2012. Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever. International journal of immunopathology and pharmacology, 25 (4), 1121–1130.
- Bhat, A., et al., 2009. Colchicine revisited. Annals of the New York Academy of Sciences, 1173, 766–773.
- Bouabdallaoui, N., et al., 2020. Time-to-treatment initiation of colchicine and cardiovascular outcomes aftermyocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European heart journal, 41 (42), 4092–4099.
- Cerquaglia, C., et al., 2005. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current drug targets inflammation and allergy, 4 (1), 117–124.
- Clinical trial: Greece., 2021. The Greek Study in the Effects of Colchicine in Covid-19 Complications Prevention (GRECCO-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04326790 [Accessed on 24 January 2021].
- Clinical trial: The ECLA PHRI COLCOVID Trial., 2021. Effects of colchicine on moderate/high-risk hospitalized COVID-19 patients (COLCOVID). Available from: https://clinicaltrials.gov/ct2/show/NCT04328480 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier NCT04367168., 2021. Colchivid. Available from: https://clinicaltrials.gov/ct2/show/NCT04367168 [accessed on 24 January 2021].
- ClinicalTrials.gov Identifier NCT04403243., 2021. Colchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT). Available from: https://clinicaltrials.gov/ct2/show/NCT04403243 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT02551094., 2021. Colchicine Cardiovascular Outcomes Trial (COLCOT). Available from: https://clinicaltrials.gov/ct2/show/NCT02551094 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT02898610., 2021. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE). Available from: https://clinicaltrials.gov/ct2/show/NCT02898610 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT03704181., 2021. Colchicine for Patients With Chagas’ Disease (B1 Stage) (COACH). Available from: https://clinicaltrials.gov/ct2/show/NCT03704181 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04056039., 2021. Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients with Rheumatoid Arthritis. (ACAR1). Available from: https://clinicaltrials.gov/ct2/show/NCT04056039 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04181996., 2021. Canadian Study of Arterial Inflammation in Patients With Diabetes and Vascular Events: EvaluatioN of Colchicine (CADENCE). Available from: https://clinicaltrials.gov/ct2/show/NCT04181996 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04322565., 2021. Colchicine Counteracting Inflammation in COVID-19 Pneumonia (ColCOVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04322565 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04322682., 2021. Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA). Available from: https://clinicaltrials.gov/ct2/show/NCT04322682 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04324463., 2021. Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (ACTCOVID19). Available from: https://clinicaltrials.gov/ct2/show/NCT04324463 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04326790., 2021. Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease (ColchiVID). Available from: https://clinicaltrials.gov/ct2/show/NCT04326790 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04350320., 2021. Trial to Study the Benefit of Colchicine in Patients With COVID-19 (COL-COVID). Available from: https://clinicaltrials.gov/ct2/show/NCT04350320 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04355143., 2021. Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04355143 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04360980., 2021. The effects of standard protocol with or without colchicine in Covid-19 infection. Available from: https://clinicaltrials.gov/ct2/show/NCT04360980 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04363437., 2021. Colchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (COMBATCOVID19). Available from: https://clinicaltrials.gov/ct2/show/NCT04363437 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04375202., 2021. Colchicine in COVID-19: a Pilot Study (COLVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04375202 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04381936., 2021. Randomised Evaluation of COVID-19 Therapy (RECOVERY). Available from: https://clinicaltrials.gov/ct2/show/NCT04381936 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04416334., 2021. Preemptive therapy with colchicine in patients older than 60 years with high risk of severe pneumoniae due to coronavirus (COLCHI-COVID). Available from: https://clinicaltrials.gov/ct2/show/NCT04416334 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04527562., 2021. Colchicine in Moderate Symptomatic COVID-19 Patients (COLCOVIDBD). Available from: https://clinicaltrials.gov/ct2/show/NCT04527562 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04603690., 2021. Study to Investigate the Benefits of Colchicine in Patients With COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04603690 [Accessed on 24 January 2021].
- ClinicalTrials.gov Identifier: NCT04667780., 2021. Study to investigate the treatment effect of colchicine in patients with COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04667780 [Accessed on 24 January 2021].
- Colchicine 500mcg tablets., 2021. Summary of product characteristics (SmPC). Available from: https://www.medicines.org.uk/emc/product/6415/smpc#gref [Accessed on 24 January 2021].
- COLCORONA trial., 2021. Colchicine reduces the risk of COVID-19-related complications. Available from: https://www.icm-mhi.org/en/pressroom/news/colchicine-reduces-risk-covid-19-related-complications [Accessed on 24 January 2021].
- Colcrys Label., 2012. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf [Accessed on 24 January 2021].
- Davis, M.W. and Wason, S., 2014. Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions. Clinical drug investigation, 34 (4), 259–267.
- Davis, M.W., Wason, S., and Digiacinto, J.L., 2013. Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating gout. The consultant pharmacist, 28 (3), 176–183.
- Deftereos, S., et al., 2015. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation, 132 (15), 1395–1403.
- Deftereos, S., et al., 2012. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. Journal of the American College of Cardiology, 60 (18), 1790–1796.
- Deftereos, S., et al., 2013. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. Journal of the American College of Cardiology, 61 (16), 1679–1685.
- Deftereos, S., et al., 2020a. The Greek study in the effects of colchicine in Covid-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic journal of cardiology, 61 (1), 42–45.
- Deftereos, S., et al., 2020b. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Network Open, 3 (6), e2013136.
- Deftereos, S., et al., 2020c. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? European heart journal. Cardiovascular pharmacotherapy, 6 (4), 255.
- Della-Torre, E., et al., 2020. Treating COVID-19 with colchicine in community healthcare setting. Clinical immunology, 217, 108490.
- Ehrenfeld, M., et al., 1982. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial mediterranean fever). Digestive diseases and sciences, 27 (8), 723–727.
- European Medicines Agency., 2019. EMA/CHMP/35552/2019. Available from: https://www.ema.europa.eu/en/ documents/scientific-guideline/colchicine-tablet-05-mg-1-mg-product-specific-bioequivalence-guidance_en.pdf [Accessed on 23 March 2021].
- Ferron, G.M., et al., 1996. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. Journal of clinical pharmacology, 36 (10), 874–883.
- Finkelstein, Y., et al., 2010. Colchicine poisoning: the dark side of an ancient drug. Clinical toxicology, 48 (5), 407–414.
- Gasparyan, A.Y., et al., 2015. Colchicine as an anti-inflammatory and cardioprotective agent. Expert opinion on drug metabolism & toxicology, 11 (11), 1781–1794.
- Girre, C., et al., 1989. Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. Fundamental & clinical pharmacology, 3 (5), 537–543.
- Gloperba Label., 2021. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf [Accessed on 24 January 2021].
- Gül, A., 2014. Treatment of familial Mediterranean fever: colchicine and beyond. The Israel Medical Association journal, 16 (5), 281–284.
- Karalis, V., Ismailos, G., and Karatza, E., 2020. Chloroquine dosage regimens in patients with COVID-19: safety risks and optimization using simulations. Safety science, 129, 104842.
- Karatza, E., et al., 2021. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. Xenobiotica; the fate of foreign compounds in biological systems, 51 (2), 127–138.
- Leighton, J.A., et al., 1991. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology, 14 (6), 1013–1015.
- Lennerz, C., et al., 2017. Colchicine for primary prevention of atrial fibrillation after open-heart surgery: systematic review and meta-analysis. International journal of cardiology, 249, 127–137.
- Leung, Y.Y., Yao Hui, L.L., and Kraus, V.B., 2015. Colchicine-Update on mechanisms of action and therapeutic uses. Seminars in arthritis and rheumatism, 45 (3), 341–350.
- Levy, M., Spino, M., and Read, S.E., 1991. Colchicine: a state-of-the-art review. Pharmacotherapy, 11 (3), 196–211.
- Lopes, M., et al., 2020. Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. Available from: https://www.medrxiv.org/content/10.1101/2020.08.06.20169573v2 [Accessed on 24 January 2021].
- Martinon, F., et al., 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440 (7081), 237–241.
- Masson, W., et al., 2020. Role of colchicine in stroke prevention: an updated meta-analysis. Journal of stroke and cerebrovascular diseases, 29 (5), 104756.
- mlxR: Simulation of Longitudinal Data., 2021. R package. Available from: https://cran.r-project.org/web/packages/mlxR/index.html [Accessed on 23 March 2021].
- Molad, Y., 2002. Update on colchicine and its mechanism of action. Current rheumatology reports, 4 (3), 252–256.
- Nidorf, S.M., et al., 2013. Low-dose colchicine for secondary prevention of cardiovascular disease. Journal of the American College of Cardiology, 61 (4), 404–410.
- Nidorf, S.M., et al., 2020. Colchicine in patients with chronic coronary disease. New England journal of medicine, 383 (19), 1838–1847.
- Nidorf, M. and Thompson, P.L., 2007. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. The American journal of cardiology, 99 (6), 805–807.
- Niel, E. and Scherrmann, J.M., 2006. Colchicine today. Joint bone spine, 73 (6), 672–678.
- Nuki, G., 2008. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Current rheumatology reports, 10 (3), 218–227.
- Ozen, S., et al., 2016. EULAR recommendations for the management of familial Mediterranean fever. Annals of the rheumatic diseases, 75 (4), 644–651.
- Perinel, S., et al., 2020. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clinical infectious diseases, 71 (16), 2227–2229.
- Peters, R.S., Lehman, T.J., and Schwabe, A.D., 1983. Colchicine use for familial Mediterranean fever. Observations associated with long-term treatment. The western journal of medicine, 138 (1), 43–46.
- PRINCIPLE trial., 2021. PRINCIPLE COVID-19 treatments trial widens to under 50s and adds colchicine. https://www.principletrial.org/news/principle-covid-19-treatments-trial-widens-to-under-50s-adds-colchicine [Accessed on 23 March 2021].
- Putterman, C., et al., 1991. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Seminars in arthritis and rheumatism, 21 (3), 143–155.
- Raynor, A. and Askari, A.D., 1980. Behçet’s disease and treatment with colchicine. Journal of the American Academy of Dermatology, 2 (5), 396–400.
- Rochdi, M., et al., 1994. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. European journal of clinical pharmacology, 46 (4), 351–354.
- Roddy, E., et al., 2020. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Annals of the rheumatic diseases, 79 (2), 276–284.
- Roubille, F., et al., 2013. Colchicine: an old wine in a new bottle? Anti-inflammatory & anti-allergy agents in medicinal chemistry, 12 (1), 14–23.
- Saleh, Z. and Arayssi, T., 2014. Update on the therapy of Behçet disease. Therapeutic advances in chronic disease, 5 (3), 112–134.
- Sapra, S., et al., 2013. Colchicine and its various physicochemical and biological aspects. Medicinal chemistry research, 22, 531–547.
- Scarsi, M., et al., 2020. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Annals of the rheumatic diseases, 79 (10), 1286–1289.
- Schwier, N.C., 2015. Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. American journal of cardiovascular drugs, 15 (5), 295–306.
- Slobodnick, A., et al., 2018. Update on colchicine, 2017. Rheumatology, 57 (1), i4–i11.
- Solak, Y., Acikgoz, S.B., and Yildirim, M., 2015a. Colchicine toxicity: an exaggerated reality? The American journal of medicine, 128 (8), e11.
- Solak, Y., Acikgoz, S.B., and Yildirim, M., 2015b. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clinical drug investigation, 35 (2), 149.
- Spartalis, M., et al., 2018. The beneficial therapy with colchicine for atherosclerosis via anti-inflammation and decrease in hypertriglyceridemia. Cardiovascular & hematological agents in medicinal chemistry, 16 (2), 74–80.
- Tardif, J.C., et al., 2019. Efficacy and safety of low-dose colchicine after myocardial infarction. The New England journal of medicine, 381 (26), 2497–2505.
- Terkeltaub, R.A., 2009. Colchicine update: 2008. Seminars in arthritis and rheumatism, 38 (6), 411–419.
- Terkeltaub, R.A., et al., 2010. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and rheumatism, 62 (4), 1060–1068.
- Terkeltaub, R.A., et al., 2011. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis and rheumatism, 63 (8), 2226–2237.
- Thomas, G., et al., 1989. Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. European journal of clinical pharmacology, 37 (1), 79–84.
- Tong, D.C., et al., 2020. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation, 142 (20), 1890–1900.
- Tong, D.C., Wilson, A.M., and Layland, J., 2016. Colchicine in cardiovascular disease: an ancient drug with modern tricks. Heart, 102 (13), 995–1002.
- Wallace, S.L. and Ertel, N.H., 1973. Plasma levels of colchicine after oral administration of a single dose. Metabolism: clinical and experimental, 22 (5), 749–753.
- Wallace, S.L., Omokoku, B., and Ertel, N.H., 1970. Colchicine plasma levels. Implications as to pharmacology and mechanism of action. The American journal of medicine, 48 (4), 443–448.
- Wason, S., Mount, D., and Faulkner, R., 2014. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clinical drug investigation, 34 (12), 845–855.
- Woo, M.Y., et al., 2012. Differential effects of colchicine in blood mononuclear cells of patients with Behçet disease in relation to colchicine responsiveness. The British journal of dermatology, 167 (4), 914–921.
- Yao, X., et al., 2020. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical infectious diseases, 71 (15), 732–739.